| 2.1 Subgroup analysis: participants with a first episode |
29 |
4113 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.33, 0.46] |
| 2.1.1 first episode |
8 |
528 |
Risk Ratio (M‐H, Random, 95% CI) |
0.47 [0.38, 0.58] |
| 2.1.2 not first episode |
24 |
3585 |
Risk Ratio (M‐H, Random, 95% CI) |
0.38 [0.31, 0.46] |
| 2.2 Subgroup analysis: participants in remission at baseline |
29 |
4113 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.32, 0.46] |
| 2.2.1 in remission |
10 |
1050 |
Risk Ratio (M‐H, Random, 95% CI) |
0.44 [0.33, 0.60] |
| 2.2.2 not in remission |
19 |
3063 |
Risk Ratio (M‐H, Random, 95% CI) |
0.36 [0.30, 0.44] |
| 2.3 Subgroup analysis: various durations of stability before entering the study |
24 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.3.1 stable at least 1 month |
6 |
574 |
Risk Ratio (M‐H, Random, 95% CI) |
0.32 [0.20, 0.50] |
| 2.3.2 stable at least 3 months |
10 |
2250 |
Risk Ratio (M‐H, Random, 95% CI) |
0.34 [0.26, 0.43] |
| 2.3.3 stable at least 6 months |
1 |
20 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.04, 2.69] |
| 2.3.4 stable at least 12 months |
5 |
326 |
Risk Ratio (M‐H, Random, 95% CI) |
0.31 [0.17, 0.57] |
| 2.3.5 stable at least 3 to 6 years |
2 |
54 |
Risk Ratio (M‐H, Random, 95% CI) |
0.38 [0.18, 0.78] |
| 2.4 Subgroup analysis: abrupt withdrawal versus tapering |
29 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.4.1 Abrupt withdrawal |
18 |
2348 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.35, 0.53] |
| 2.4.2 Taper |
11 |
1765 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.24, 0.44] |
| 2.5 Subgroup analysis: single antipsychotic drugs |
29 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.5.1 Chlorpromazine |
2 |
406 |
Risk Ratio (M‐H, Random, 95% CI) |
0.44 [0.36, 0.55] |
| 2.5.2 Fluphenazine depot |
6 |
296 |
Risk Ratio (M‐H, Random, 95% CI) |
0.23 [0.14, 0.39] |
| 2.5.3 Haloperidol depot |
1 |
43 |
Risk Ratio (M‐H, Random, 95% CI) |
0.14 [0.04, 0.55] |
| 2.5.4 Various, mixed groups of antipsychotic drugs |
10 |
705 |
Risk Ratio (M‐H, Random, 95% CI) |
0.42 [0.27, 0.65] |
| 2.5.5 Quetiapine |
1 |
178 |
Risk Ratio (M‐H, Random, 95% CI) |
0.48 [0.34, 0.69] |
| 2.5.6 Paliperidone |
4 |
1256 |
Risk Ratio (M‐H, Random, 95% CI) |
0.37 [0.31, 0.44] |
| 2.5.7 Aripiprazole |
2 |
549 |
Risk Ratio (M‐H, Random, 95% CI) |
0.35 [0.14, 0.86] |
| 2.5.8 Brexpiprazole |
1 |
202 |
Risk Ratio (M‐H, Random, 95% CI) |
0.36 [0.23, 0.56] |
| 2.5.9 Ziprasidone |
1 |
278 |
Risk Ratio (M‐H, Random, 95% CI) |
0.50 [0.39, 0.64] |
| 2.5.10 Cariprazine |
1 |
200 |
Risk Ratio (M‐H, Random, 95% CI) |
0.54 [0.38, 0.77] |
| 2.6 Subgroup analysis: depot versus oral drugs |
26 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.6.1 depot |
10 |
1705 |
Risk Ratio (M‐H, Random, 95% CI) |
0.30 [0.23, 0.39] |
| 2.6.2 oral |
16 |
2187 |
Risk Ratio (M‐H, Random, 95% CI) |
0.46 [0.38, 0.55] |
| 2.7 Subgroup analysis: first‐ versus second‐generation antipsychotic drugs |
29 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.7.1 First‐generation antipsychotic drugs |
18 |
1430 |
Risk Ratio (M‐H, Random, 95% CI) |
0.35 [0.25, 0.48] |
| 2.7.2 Second‐generation antipsychotic drugs |
11 |
2683 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.32, 0.48] |
| 2.8 Subgroup analysis: appropriate versus unclear allocation concealment |
29 |
4113 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.32, 0.46] |
| 2.8.1 appropriate allocation concealment |
13 |
2708 |
Risk Ratio (M‐H, Random, 95% CI) |
0.37 [0.30, 0.45] |
| 2.8.2 unclear allocation concealment |
16 |
1405 |
Risk Ratio (M‐H, Random, 95% CI) |
0.41 [0.30, 0.54] |
| 2.9 Subgroup analysis: blinded versus open trials |
29 |
4113 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.32, 0.46] |
| 2.9.1 blinded trials |
27 |
3856 |
Risk Ratio (M‐H, Random, 95% CI) |
0.40 [0.33, 0.48] |
| 2.9.2 unblinded trials |
2 |
257 |
Risk Ratio (M‐H, Random, 95% CI) |
0.26 [0.17, 0.39] |
